Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ANG Lifesciences India has informed that the company has already crossed 200 cr revenue milestone and going forward, the company is expecting similar robust growth in coming quarters. The Company is expected to post turnover around Rs 400-450 cr. with expected IT in measurable terms Rs 15 cr approx in F.Y. 2021-22. Also, the Company has been able to show handsome growth backed by persistent and focused efforts by the management in its goal of maintaining the growth trend on going forward.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1662.00 |
| Dr. Reddys Lab | 1212.00 |
| Cipla | 1225.30 |
| Zydus Lifesciences | 925.00 |
| Lupin | 2290.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: